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Abstract:  Neuregulins are a family of growth factor domain proteins that are structurally related to the epidermal 
growth factor.  Accumulating evidence has shown that neuregulins have cyto- and neuroprotective properties in 
various cell types.  In particular, the neuregulin-1 βeta (NRG1-β) isoform is well documented for its anti-
inflammatory properties in rat brain after acute stroke episodes. Pentachlorophenol (PCP) is an organochlorine 
compound that has been widely used as a biocide in several industrial, agricultural, and domestic applications.  
Previous investigations from our laboratory have demonstrated that PCP exerts both cytotoxic and mitogenic 
effects in human liver carcinoma (HepG2) cells, primary catfish hepatocytes and AML 12 mouse hepatocytes.  We 
have also shown that in HepG2 cells, PCP has the ability to induce stress genes that may play a role in the 
molecular events leading to toxicity and tumorigenesis.  In the present study, we hypothesize that NRG1-β will 
exert its cytoprotective effects in PCP-treated AML 12 mouse hepatocytes by its ability to suppress the toxic 
effects of PCP.  To test this hypothesis, we performed the MTT-cell respiration assay to assess cell viability, and 
Western-blot analysis to assess stress-related proteins as a consequence of PCP exposure.  Data obtained from 48 
h-viability studies demonstrated a biphasic response; showing a dose-dependent increase in cell viability within 
the range of 0 to 3.87 µg/mL, and a gradual decrease within the concentration range of 7.75 to 31.0 µg/mL in 
concomitant treatments of  NRG1-β+PCP and PCP.  Cell viability percentages indicated that NRG1-β+PCP-
treated cells were not significantly impaired, while PCP-treated cells were appreciably affected; suggesting that 
NRG1-β has the ability to suppress the toxic effects of PCP.  Western Blot analysis demonstrated the potential of 
PCP to induce oxidative stress and inflammatory response (c-fos), growth arrest and DNA damage (GADD153), 
proteotoxic effects (HSP70), cell cycle arrest as consequence of DNA damage (p53), mitogenic response (cyclin-
D1), and apoptosis (caspase-3).  NRG1-β exposure attenuated stress-related protein expression in PCP-treated 
AML 12 mouse hepatocytes.  Here we provide clear evidence that NRG1-β exerts cytoprotective effects in AML 
12 mouse hepatocytes exposed to PCP. 
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Introduction 
 
Neuregulins are transmembrane polypeptide growth 
factors with structural epidermal growth factor (EGF)-
like domains.  The neuregulin EGF-like domain binds  
with four  estrogene receptor B (ErbB receptor)-tyrosine 
kinases, thereby orchestrating a growth factor signaling 
system essential for cell growth, differentiation, and 
survival [1-3].  It is well documented that neuregulin 
interaction with ErbB receptors can result in receptor 
dimerization, tyrosine phosphorylation, and subsequent 
activation of intracellular signaling pathways [2, 4]. 
Neuregulins are highly expressed in the nervous system, 
where they play crucial roles in development, 
maintenance, and repair [5]. Moreover, neuronal 
migration, synaptogenesis, receptor subunit composition, 
and the proliferation and survival of Schwann cells, and 
oligodendrocytes are influenced by neuregulin-ErbB 
receptor interaction [5, 6].  For example, neuregulin 
diminishes autoimmune demyelination, promotes 
oligodendrocyte progenitor expansion, and enhances 
remyelination in the central nervous system [7]. 
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Neuregulins (NRG) are synthesized from alternative 
spliced transcripts of one of four known (neuregulin-1,-
2, -3, and -4) genes.  To date, neuregulin-1 (NRG1) gene 
transcripts encoding over 15 different isoforms have 
been identified [8].  NRG1 is also called neu 
differentiation factor, heregulin, or glial growth factor, 
and has acetylcholine-receptor-inducing activity.  More 
specifically, the NRG1 gene expresses a α- or β-type 
EGF-like domain that preferentially binds to erbB3 and 
erbB4 tyrosine kinase receptors [1, 9, 10].  The NRG1-β 
isoform is predominant in the central nervous system and 
has been shown to participate in development, survival, 
and metabolism in neuron and glial cells [6, 11]. 
Accumulating evidence has shown that exogenous 
NRG1-β treatment can exert cyto- and neuroprotective 
effects in neuronal cells [4, 12, 13].  In addition, NRG1-β 
treatment prevents macrophage and microglial infiltration 
and astrocytic activation following focal ischemic stroke 
in the rat [12].  The same study also reported that the 
neuroprotective activity of NRG1-β can suppress 
interleukin-1 beta mRNA levels [12]. It has been 
demonstrated that NRG1-β blocks the induction of pro-
inflammatory and stress genes provoked by ischemia [13]. 
In the presence of NRG1-β, Schwann cells infected with 
the N70-Ets DNA plasmid show minimum cell death [4]. 
The ability of NRG1-β to protect myocytes against 
anthracyline- and β-adrenergic receptor-induced cell 
injury and death is well documented [14-16]. 
Pentachlorophenol (PCP), an organochlorine 
fungicide, is a probable human carcinogen-Group B2 [17], 
based on suggestive evidence of carcinogenicity from 
laboratory animal studies.  Previous findings from our 
laboratory have demonstrated that PCP has the ability to 
undergo Phase I biotransformation in the liver (CYP1A1 
and XRE), to cause cell proliferation (c-fos), to cause 
growth arrest and DNA damage (GADD153 and p53), to 
influence the toxicokinetics of metal ions (HMTIIA), and to 
induce proteotoxic effects (HSP70 and GRP78) in HepG2 
cells [18].  We have also reported that PCP exerts both 
cytotoxic and mitogenic effects in human liver carcinoma 
(HepG2) cells, primary catfish hepatocytes, and AML 12 
mouse hepatocytes [19, 20].  In the present study, we 
hypothesized that NRG1-β will exert a cytoprotective effect 
in PCP-treated AML 12 mouse hepatocytes in vitro.  
 
Materials and Methods  
 
Chemicals  
 
Pentachlorophenol (C6Cl5OH, CAS No. 87-86-5, 
Lot No. 01530TS), with purity 98.0% was purchased 
from Sigma-Aldrich Chem CO., (St. Louis, Missouri).  
Neuregulin 1-βeta (a gift from Dr. Byron Ford, 
Morehouse School of Medicine, Atlanta, GA; this is 
referred to as NRG1- β in the text).  Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Lot No. 
AQF24057) and Dulbecco’s phosphate buffered saline 
(PBS) (Lot No. AQE23425) was purchased from 
Hyclone (Logan, Utah).  Tissue culture supplements 
were purchased from American Type Culture Collection 
(ATCC) Manassas, VA.  Thiazolyl blue trazolium 
bromide CAS 298-93-1, purity 97.5%, β-
mercaptoethanol, and dimethyl sulfoxide were purchased 
from Sigma-Aldrich (St. Louis, Missouri). Twelve 
percent SDS-PAGE gels were obtained from ISC 
BioExpress (Kaysville, UT). HSP70 primary monoclonal 
antibody was purchased from Calbiochem (La Jolla, 
CA). c-fos, caspase-3, cyclin D1, and p53, primary 
monoclonal antibodies, were purchased from Oncogene 
Research Products (San Diego, CA).  The GADD153 
primary polyclonal antibody was obtained from Abcam 
Inc. (Cambridge, MA). Alkaline phosphatase conjugated 
goat-anti-mouse IgG secondary antibody, and 
BCIP/NBT color development substrate were purchased 
from Promega (Madison, WI). Reagents for protein 
determination, gel electrophoresis, and Western blot 
analysis were obtained from Bio-Rad (Hercules, CA).    
 
Cell Culture  
 
Alpha mouse liver 12 (AML 12) hepatocyte cultures 
were established from a mouse transgenic for human 
transforming growth factor α (ATCC CRL-2254, Manassas, 
VA).   The cells were stored in liquid nitrogen until future 
use.  The content of each vial was transferred to a 75 cm2 
tissue culture flask diluted with DMEM, supplemented with 
10% fetal bovine serum (FBS) and 1% streptomycin-
penicillin, and incubated at 37oC under an atmosphere of 
5% CO2 with humidified air to allow the cells to grow and 
form a monolayer in the flask.  Subsequently, cells grown 
to 80-95% confluence were washed with PBS, trypsinized 
with 5 mL of 0.25% (w/v) EDTA, diluted, counted, and 
seeded in 96-well microtiter tissue culture plates (5 x 105 
cells/well) for cell viability studies. 
 
Cell Viability Experiments  
  
To establish cell viability in hepatocytes treated with 
concomitant doses of NRG1-β+PCP and PCP. 
Administered doses ranged from 0 to 31.0 µg/mL for an 
exposure period of 48h.  Prior to exposure, cells (5 x 105) 
were maintained with medium containing 10% FBS.  On 
the day of exposure, FBS-medium was removed and 
replaced with serum-free medium.  In the concomitant 
experiments, a 0.01 nM NRG1-β was added to varying 
doses of PCP.  Cell viability was evaluated using a 
colorimetric assay in which the reduction of a tetrazolium 
salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT) by the mitochondrial dehydrogenase of 
living cells was detected.  In this assay, metabolically active 
cells were able to convert MTT to water-insoluble dark-
blue formazan crystals.  Viable cells were quantified by 
dissolution in 100% dimethyl sulfoxide and measured by 
absorbance with the wavelength set at 550 nm; using an 
EL 800 Model ELISA plate reader (Bio-Tek Instruments 
Inc., Winooski, Vermont) [21].  The toxic effect of PCP at 
different doses was expressed as the percentage of the 
absorbance determined for control cells incubated with the 
corresponding vehicle. 
    
Sample Collection and Protein Determination 
 
Cells grown to 80-95% confluence were washed 
with PBS, trypsinized with 5 mL of 0.25% (w/v) EDTA, 
diluted, counted, and seeded in two  48-well microtiter 
tissue culture plates (1 x 106 cells/well).  Whole cells 
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were treated with PCP and NRG1-β+PCP (0-16 µg/mL) 
for 48 h.   Cells were resuspended in 300 µL of sample 
buffer (0.2 mol/L Tris, pH 6.8, 1% SDS, 30% glycerol, 
7.5% β-mercaptoethanol, 0.1% bromophenol blue) per 
well.  Cells were mechanically dislodged, transferred to 
microcentrifuge tubes, and heated at 95oC for 10 min. 
Samples were frozen until future use.  The Bradford 
protein assay in a microtiter plate format was used for 
the determination of protein concentrations (20-25 µg) in 
samples.  The total protein concentrations for cell lysates 
were quantitatively measured at 550 nm absorbance; 
using the Bio-Tek Model – EL 800 microplate reader.  
 
Western Blot Analysis for Identification of Specific 
Cellular Proteins 
 
The Western-blot analysis was conducted to 
determine specific cellular response gene proteins (c-fos, 
caspase-3, cyclin D1, GADD153, HSP70, and p53) at 48 
h of PCP and NRG1-β+PCP exposure to AML 12 mouse 
hepatocytes.  Twenty micrograms of total protein from 
whole cells extracts were denatured in load buffer and 
separated using a 12% SDS–polyacramide gradient gel.  
After migration, gels were equilibrated in transfer buffer 
(20 mM Tris base, 150 mM glycine, 20% methanol, pH 
8) and separated proteins were transferred onto a 
nitrocellulose membrane. Subsequently, the 
nitrocellulose membrane was blocked (10 mL Tris-
buffered saline, 0.1 Tween-20 [TBST] with 5% nonfat 
dry milk) for 1 h at room temperature.  Detection of 
membrane-bound proteins induced by PCP and 
NRG1+PCP was carried out using specific primary 
antibodies that recognize proteins of interest (c-fos 
15:1000, caspase-3  4:1000, cyclin D1 4:1000, 
GADD153 1:1000, HSP70 1:1000, and p53 1:1000).  
Subsequently, the reactions were reprobed with a 
secondary alkaline conjugated 1:7500 anti-mouse IgG 
antibody.  BCIP/NBT color substrate was incorporated 
to develop protein bands.  Immunoblot 1-D protein 
bands were assessed for relative abundance by TotalLab 
computer software (Nonlinear USA Inc. Durham, NC). 
 
Statistical Analysis 
 
Absorbance readings of 550 nm from cell viability 
experiments were transformed into percentages to 
compare the viability of treated cells to that of untreated 
(control) cells.  Graphs were made to illustrate the dose-
response relationship with respect to cytotoxicity or cell 
viability.  Standard deviations were determined, and the 
Student’s t-test values were computed to determine if 
there were significant differences in cell viability in 
PCP- and NRG1-β+PCP-treated cells compared to 
control cells (0, 0.01 nM NRG1-β).   A value of p<0.05 
was considered significant.  
 
Results 
 
Comparison of Untreated and NRG1-βTtreated Mouse 
Hepatocytes 
  
The comparison of untreated and NRG1-β-treated 
mouse hepatocytes in vitro is shown in Figure 1.  
Neuregulin has the ability to elicit cell proliferation 
through interaction with members of the ErbB family of 
receptor tyrosine kinases [5, 6]. Therefore, it was of 
interest to determine whether NRG1-β treatment of 
hepatocyte culture in vitro could promote a mitogenic 
response.  Cells were treated with 0.01 nM NRG1-β or 
left untreated (0) for 24- and 48 h periods according to 
the methodology section.  The cells were assayed for 
viability by using MTT incorporation.  The mean 
absorbance was recorded as optical density at 550 nm for 
untreated and NRG1-β treated cells.  The optical 
densities for 24 h untreated (0) cells and 0.01 nM NRG1-
β were recorded at 0.71 and 0.64, respectively.   The 48 
h optical density was recorded at 0.66 and 0.67 
respectively for untreated (0) cells and 0.01 nM NRG1-
β. Data obtained from these experiments demonstrated 
that differences in the mean absorbance of untreated and 
NRG1-β-treated cells were not statistically significant 
(p>0.05).  Our findings suggest that AML 12 mouse 
hepatocytes do not significantly proliferate in response 
to NRG1-β treatment in serum-free medium. 
 
 
Figure 1:  Comparison of untreated and NRG1-β-
treated AML 12 mouse hepatocytes.  NRG1-β-treated (10 
nM NRG1-β; 1:1000) hepatocytes were compared to 
untreated (0) cells for 24- and 48 h. Hepatocytes were 
maintained in DMEM medium with 10%  FBS 
supplement.  On day of exposure, FBS-medium was 
replaced with serum-free medium. The MTT-assay was 
used to determine absorbance at 550 nm after 24- and 48 
h exposure periods.  Absorbance readings are expressed 
as optical density.  Each bar represents the mean + S.D 
(n=3 independent experiments; p>0.05). 
 
Effects of NRG1-β on PCP-Treated Mouse Hepatocytes 
  
The effects of NRG1-β on PCP toxicity to AML 12 
mouse hepatocytes are shown in Figure 2.  Within the 
dose range of 0-31.0 µg/mL, a biphasic-response 
relationship was observed in both NRG1-β+PCP- and 
PCP-treated cells.  The percentages for cell viability 
were recorded as 100.0 + 0.0%, 188.0 + 0.3%, 129.0 + 
0.3%, 102.0 + 0.3%,  67.0 + 0.2%, and 72.0 + 0.1% at 0, 
1.93, 3.87, 7.75, 15.5, and 31.0 µg/mL respectively for 
NRG1-β+PCP.  Cell viability percentages for PCP 
treatments were recorded as 100 + 0.0%, 173.0 + 0.4%, 
116.0 + 0.4%, 87.0 + 0.2%, 60.0 + 0.2%, and 48.0 + 
0.1% at 0, 1.93, 3.87, 7.75, 15.5, and 31.0 µg/mL, 
respectively.  The highest viability was achieved at 1.93 
Int. J. Environ. Res. Public Health 2006, 3(1) 
 
14
µg/mL. Cell viability percentages indicated that NRG1-
β+PCP-treated cells had not been significantly impaired 
(except for the highest PCP concentration), while PCP-
treated cells were appreciably reduced.  Data obtained 
from this experiment strongly suggest that NRG1-β has 
the ability to rescue cell survival after PCP treatment by 
suppressing the toxic effects of PCP.   
 
 
 
Figure 2:  Effect of NRG1-β on PCP toxicity in AML 12 
Mouse Hepatocytes. Cells were treated for 48hrs with 
PCP in the presence or absence of NRG1-β (0.01 nM).  
The number of metabolically active cells was determined 
by the MTT incorporation.  The data are expressed as 
percentages of cell viability.  Each point represents a 
mean value and standard deviation of three independent 
experiments (n = 3 independent experiments; 8 
replications per treatment).  *Significantly different (p < 
0.05) from NRG1-β-treatment. 
 
 
Western Blot and Densitometric Analyses for c-fos 
Expression  
  
In the studies herein, mouse hepatocytes were 
acutely exposed to PCP and NRG1-β+PCP treatments 
(0, 8, 16 µg/mL) and compared to the untreated (0) and 
0.01 nM NRG1-β to determine the magnitude of changes 
in specific protein expressions. In each experiment, basal 
levels of specific protein expression were not detected in 
untreated and NRG1-β–treated cultures.  Western-blot 
and densitometric analyses were performed according to 
the methodology section.  The 62-kDa c-fos proto-
oncogene is recognized as an immediate early gene and 
has been identified as a transcription factor that responds 
to DNA-damage [22]. We have previously reported that 
PCP has the ability to markedly induce a dose-dependent 
upregulation of the c-fos gene protein in HepG2 cells and 
primary catfish hepatocytes [18, 19, 23].  
Western-blot and densitometric analyses of c-fos 
expression in PCP- and NRG1-β + PCP-treated AML 12 
mouse hepatocytes for 48 h are shown in Figure 3  upon 
48h of exposure, a dose-dependent upregulation of the c-
fos protein was observed in concomitant treatments of 
PCP and NRG1-β+PCP. The magnitude of c-fos 
expression was highly correlated with increased levels of 
PCP toxicity.  For example, densitometric analysis 
showed a significant (p<0.05) increase of c-fos relative 
abundance of 83,714 at 8 µg PCP/mL, 54,115 at 16 µg 
NRG1-β+PCP/mL, and 229,374 at 16 µg PCP/mL. We 
did not detect the c-fos protein at 8 µg NRG1-
β+PCP/mL; suggesting that NRG1-β attenuates PCP-
stimulated c-fos expression at low levels of PCP-toxicity. 
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Figure 3: Expression and relative abundance of the 62 
kDa c-fos in AML 12 mouse hepatocytes exposed to PCP 
and NRG1-β + PCP for 48 h. AML 12 mouse 
hepatocytes were treated with 8 µg/mL and 16 µg/mL 
concomitant treatments of PCP and NRG1-β + PCP.   c-
fos protein identification was assessed following 
exposure incubation period of 48 h. Inset shows a 
representative Western blot analysis. Each point 
represents a mean value and standard deviation of three 
experiments. *Significantly different (p < 0.05) from 
untreated (0 µg/mL PCP) and NRG1-β (1:1000) treated 
cells. 
 
 
Western Blot and Densitometric Analyses for HSP70 
Expression 
  
HSP70, a member of the heat shock protein family, 
is a highly conservative molecular chaperone with 
strategic functions that respond to conditions of 
environmental stress, including tissue damage, 
inflammation, and mutant proteins associated with 
genetic abnormalities [24].  We have previously reported 
that the overexpression of the HSP70 gene protein is a 
dose-dependent event in HepG2 cells exposed to PCP 
[18, 23].    
The expression and relative abundance of the 70-
kDa heat shock protein in AML 12 mouse hepatocytes 
exposed to PCP and NRG1-β+PCP treatments for 48 h 
are shown in Figure 4.   A dose-dependent upregulation 
of the HSP70 gene protein was demonstrated in both 
treatments of PCP and NRG1-β+PCP at 48 h.  PCP-
toxicity induced the upregulation of HSP70 at 8 µg 
PCP/mL with a relative abundance of 170,584.  
However, a drastic decrease (p<0.05) or down-regulation 
of HSP70 expression was demonstrated at 16 µg 
PCP/mL with a relative abundance of 10,000.   NRG1-β 
completely suppressed the expression of HSP70 at 8 µg 
NRG1-β+PCP/mL and 16 µg NRG1-β+PCP/mL. These 
results suggest that NRG1-β has the ability to rescue 
cells from the consequences of proteolytic activity 
induced by PCP-toxicity.  
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Figure 4: Expression and relative abundance of the 70 
kDa heat shock (HSP70) in AML 12 mouse hepatocytes 
exposed to PCP and NRG1-β + PCP for 48 h.  AML 12 
mouse hepatocytes were treated with 8 µg/mL and 16 
µg/mL concomitant treatments of PCP and NRG1-
β+PCP.   HSP70 protein identification was assessed 
following exposure incubation period of 48 h. Inset 
shows a representative Western blot analysis.  Each 
point represents a mean value and standard deviation of 
three experiments. *Significantly different (p<0.05) 
from untreated (0 µg/mL PCP) and NRG1-β (1:1000) 
treated cells. 
 
Western-Blot and Densitometric Analyses for GADD153 
Expression 
  
The GADD153 gene protein is robustly induced by 
genotoxic stress and is coordinately regulated with the 
endoplasmic reticulum (ER) [25].  The expression and 
relative abundance of the 153-kDa GADD in AML 12 
mouse hepatocytes exposed to PCP and NRG1-β+PCP 
treatments for 48 h are shown in Figure 5.  
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Figure 5: Expression and relative abundance of the 153 
kDa GADD in AML 12 mouse hepatocytes exposed to 
PCP and NRG1-β + PCP for 48 h.  AML 12 mouse 
hepatocytes were treated with 8 µg/mL and 16 µg/mL 
concomitant treatments of PCP and NRG1-β + PCP.   
GADD153 protein identification was assessed following 
exposure incubation period of 48 h.  Inset shows 
representative Western blot analysis.  Each point 
represents a mean value and standard deviation of three 
experiments.  *Significantly different (p < 0.05) from 
untreated (0 µg/mL PCP) and NRG1-β (1:1000) treated 
cells. 
We have previously reported that PCP can induce a 
dose-dependent expression of the GADD153 gene 
protein in HepG2 cells [18].   In this experiment, 
stimulated cells resulted in a dose-dependent (p<0.05) 
upregulation of the GADD153 protein with relative 
abundances of 26,411 and 40,626 respectively for 8 µg 
PCP/mL and 16 µg PCP/mL.  Conversely, the expression 
of GADD153 was completely repressed at 8 µg NRG1-
β+PCP/mL and 16 µg NRG1-β+PCP/mL.  Data obtained 
from this experiment indicated that NRG1-β has the 
ability to attenuate growth arrest and DNA-damage 
activity at low and high levels of PCP-toxicity.  
 
Western-Blot and Densitometric Analyses for p53 
Expression 
  
The 53-kDa p53 gene protein, also known as the 
tumor suppressor gene, senses DNA damage and responds 
by arresting the cell cycle [26].  Western-blot and 
densitometric analyses of the p53 gene protein in AML 12 
mouse hepatocytes exposed to PCP and NRG1-β + PCP 
for 48 h are shown in Figure 6.  We have previously 
reported that PCP has the ability to transcriptionally 
activate the p53 tumor suppressor gene in HepG2 cells 
[18, 23].  NRG1-β has the ability to repress the p53 
protein at lower levels of PCP-toxicity.  We did not detect 
the p53 expression at 8 µg NRG1-β+PCP/mL. However, 
we observed a dose-dependent increase (p<0.05) 
upregulation of the p53 protein with relative abundances 
of 9,502,  28,339 and 43,458 respectively for 8 µg 
PCP/mL, 16 µg NRG1-β+PCP/mL, and 16 µg PCP/mL; 
demonstrating the incompetence of NRG1-β to suppress 
DNA damage at higher levels of PCP toxicity. 
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Figure 6: Expression and relative abundance of p53 in 
AML 12 mouse hepatocytes exposed to PCP and NRG1-
β + PCP for 48 h.  p53 protein identification was 
assessed following exposure incubation period of 48 h. 
Inset shows representative Western blot analysis.  Each 
point represents a mean value and standard deviation of 
three independent experiments.  *Significantly different 
(p < 0.05) from untreated (0 µg/mL) and NRG1-β 
(1:1000) treated cells. 
 
Western-Blot and Densitometric Analyses for Cyclin D1 
and Caspase-3 Expression 
  
The overexpression of cyclin D1 in hepatocytes is 
indicative of G1/S transition and mitogenic response 
[27].  Expression and relative abundance of the 35–kDa 
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cyclin D1 in AML 12 mouse hepatocytes exposed to 
PCP and NRG1-β + PCP treatments for 48 h are shown 
in Figure 7.  We have previously reported that PCP has 
the ability to elicit a mitogenic response in HepG2 cells, 
primary catfish hepatocytes, and AML 12 mouse 
hepatocytes [19, 20, 23].  In this experiment, we 
observed a dose-dependent overexpression of cyclin D1 
with relative abundances of 66,371 at 8 µg NRG1-
β+PCP/mL, 42,764 at 8 µg PCP/mL, and 48,757 at 16 
µg NRG1-β+PCP/mL. This finding supports the fact that 
NRG1-β has the ability to protect hepatocytes in the 
presence of PCP. 
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Figure 7: Expression and relative abundance of cyclin 
D1 in AML 12 mouse hepatocytes exposed to PCP and 
NRG1-β + PCP for 48h. Cyclin D1 protein identification 
was assessed following exposure incubation period of 48 
h.  Inset shows a representative Western-blot analysis.  
The following values were compared to untreated (0 
µg/mL) and NRG1-β (1:1000) treated cells. 
 
The upregulation of caspase-3 expression is strongly 
associated with the readiness of cells to undergo 
apoptosis [28].  The expression and relative abundance 
of the 32-kDa caspase-3 protein in AML 12 mouse 
hepatocytes exposed to PCP and NRG1-β + PCP 
treatments for 48 h are shown in Figure 8.  In this 
experiment we observed a dose- dependent activation of 
the caspase-3 protein with relative abundances of 40, 
223 at 8 µg NRG1-β+PCP/mL, 50,160 at 8 µg PCP/mL, 
and 91,239 at 16 µg PCP/mL.  In the presence of NRG1- 
β, the caspase-3 protein was repressed or down-regulated 
at 16 µg NRG1-β+PCP/mL; demonstrating a protective 
effect of NRG1-β at higher levels of PCP exposure. 
Here, we clearly demonstrate the ability of NRG1- β to 
block programmed cell death in PCP-treated mouse 
hepatocytes. 
 
Discussion 
 
Neuregulin 1-βeta-Induced Protective Effects 
  
The present study was designed to investigate the 
protective effects of NRG1-β on PCP-induced 
cytotoxicity in AML 12 mouse hepatocytes.  To our 
knowledge, the effects of NRG1-β treatment on 
hepatocyte survival have not been previously reported.  
We have previously reported that PCP is acutely toxic 
and causes cell injury to AML 12 mouse hepatocytes 
[20].  In that study, the 48 h-LC50 was computed to be 
16.0 + 2.0 µg PCP/mL.  In the present study, we 
observed a similar biphasic response pattern with respect 
to cell viability. Our in vitro cell viability studies 
indicate that NRG1- β has a direct cytoprotective effect 
on hepatocytes against PCP-toxicity.   
The members of the NRG family are produced by 
either neuronal or mesenchymal cells, and mediate their 
effects by binding to and signaling by the ErbB family of 
receptors [2, 9].  However, we provide clear evidence 
that NRG1-β was found to display a protective effect on 
AML 12 mouse hepatocytes caused by PCP toxicity 
(Figure 2).   All NRG proteins contain an extracellular 
EGF-like domain, which is essential for bioactivity [29].   
In a previous study, NRG1-β treatment of neonatal rat 
ventricular myocytes was shown to inhibit daunorubicin-
induced apoptosis and the activation of caspase-3 [30].  
A similar investigation demonstrated the survival effects 
of NRG1-β on norepinephrine cytotoxicity in adult rat 
ventricular myocytes by suppressing beta-adrenergic 
receptor-stimulated apoptosis [31].  In the present study, 
we have demonstrated that NRG1-β has to ability to 
inhibit PCP-induced apoptosis by completely 
suppressing the activation of caspase-3 at higher levels 
of PCP toxicity (Figure 8). 
 
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
90,000
100,000
Ln2 Ln3 Ln4 Ln5 Ln6 Ln7
C
as
pa
se
3 
re
la
tiv
e 
ab
un
da
nc
e
32 kDa
Caspase3
Ln 1 = MW standard
Ln 2 = Untreated
Ln 3 = NRG1-β (1:1000)
Ln 4 = NRG1-β (1:1000) + PCP (8 µg/mL)
Ln 5 = PCP (8 µg/mL)
Ln 6 = NRG1-β (1:1000) + PCP (16 µg/mL)
Ln 7 = PCP (16 µg/mL)
        = caspase3  abundance
  Ln1        Ln2           Ln3        Ln4           Ln5          Ln6           Ln7
 
Figure 8: Expression and relative abundance of 
caspase-3 in AML 12 mouse hepatocytes exposed to PCP 
and NRG1-β + PCP for 48h. Caspase-3 protein 
identification was assessed following exposure 
incubation period of 48 h.  Inset shows a representative 
Western-blot analysis.  The following values were 
compared to untreated (0 µg/mL) and NRG1-β (1:1000) 
treated cells. 
 
NRGs and their receptors can influence a network of 
survival signaling pathways, which is likely to vary in 
many cell types.  The phosphoinositide 3-kinase (PIK3), 
which is specifically recruited by ErbB-3 and the ErbB-
1T3 chimeric receptor, is a well-known regulator of cell 
growth and survival [32].  Abundant evidence has shown 
that the protective effects of NRGs are mediated by the 
PI3K signaling pathway [33, 34, 35].  In a very recent 
study, NRG induced a significant protective effect from 
-amyloid 25–35 peptide-induced cell death [33].   The 
same study revealed that NRG treatment produced 
elevation in the levels of the antiapoptotic protein BclxL.  
The NRG-mediated BclxL elevation was regulated by 
protein kinase C (PKC).  Results from that study 
suggested that NRG might affect cell viability by using 
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two signaling pathways: activation of PI3K/PKB/AkT 
pathway and activation of PKC, which resulted in 
increasing levels of the antiapoptotic protein BclxL [33].  
More specifically, NRG1-β has been shown to have a 
prosurvival effect on cardiac myocytes via the PI3K/Akt 
pathway [34].  The NRG-β isoform is a potent Schwann 
cell survival factor that binds to and activates a 
heterodimeric ErbB2/ErbB3 receptor complex [35]. 
Moreover, corroboration that NRG is mediated by the 
PIK3 pathway was demonstrated when NRG rapidly 
signaled the phosphorylation of mitogen-activated-
protein kinase (MAPK) and the serine/threonine kinase 
Akt in serum-starved Schwann cells [35].  The same 
study used PIK3 inhibitors that blocked the NRG-
mediated rescue of Schwann cells, as well as Akt, 
MAPK, and Bad; demonstrating the involvement of the 
PIK3 pathway [35].   
 Another possible mechanism of NRG1-β against 
PCP-toxicity in mouse hepatocytes is the involvement of 
the MAPK pathway.  The MAPK pathway is thought to 
be directly responsible for regulating cell proliferation, 
differentiation, and survival. A number of investigations 
have implicated the MAPK pathway in NRG-β mediated 
survival [35, 36, 37].   A recent study demonstrated that 
NRG1-induced activation of ErbB4 stimulates the 
MAPK, PI3K, and cyclin-dependent kinase-5 (cdk5) 
pathways in cultured rat cerebellar granule neurons [37].   
MAPK is a known downstream effector of the ErbB 
receptors.  Therefore, in the present study, it is also 
possible that NRG1-β may exert its protective activity in 
PCP-treated mouse hepatocytes via the MAPK pathway.   
 Supporting evidence suggests that ErbB3 requires 
the association of other ErbB receptors or the EGFr to 
form an active signaling complex in hepatocytes [38].  
Although NRGs are not primary mitogens in rat liver, 
they could regulate differentiation during development, 
maintenance of differentiated functions during 
regeneration, or metabolism in response to nutritional 
status [38]. A previous study demonstrated that a 
recombinant peptide corresponding to the EGF domain 
of the ß-1 isoform of heregulin (NRG1-β) bound to rat 
hepatocytes via the ErbB3 receptor, induced receptor 
phosphorylation, and stimulated DNA synthesis [38].  A 
similar investigation has shown that during rat liver 
development and regeneration, diverse ErbB receptor 
proteins are expressed [39].   In the present study, cell 
survival and cytoprotective effects of NRG1-β were 
assessed by the MTT- cell respiration assay.  Cell 
viability data indicated that NRG1-β possesses a potent 
protective effect against PCP-induced cytotoxicity in 
AML 12 mouse hepatocytes (Figure 2).  We propose that 
NRG1-β protective effects in PCP-treated hepatocytes 
are orchestrated by binding to ErbB receptors, and in 
turn the PI3K or MAPK pathway is solicited. 
  
NRG1-β Effects on PCP-Induced c-fos Expression  
  
Gene expression is controlled and regulated by 
many transcription factors in order for the cell to adjust 
to environmental or genetic modifications. We present 
evidence that NRG1-β has the ability to attenuate stress-
related events as a consequence of PCP-toxicity.  
Specifically, we show that PCP induces stress-related 
gene expression and death of AML12 mouse 
hepatocytes, where NRG1-β protected them from PCP-
induced death.  To assess the cellular injury response in 
AML 12 mouse hepatocytes, we examined the effect of 
NRG1-β on the expression of stress-related gene proteins 
as a consequence of PCP-toxicity.  In this study, we 
report that an appreciable dose-dependent expression of 
the c-fos protein was observed after 48 h of exposure to 
concomitant treatments of PCP and NRG1-β+PCP 
(Figure 3, Table 1).  
 
TABLE 1:  Relative abundance of significantly up-
regulated proteins in AML 12 mouse hepatocytes 
exposed for 48 hrs to PCP in the absence or presence of 
NRG1-β (0.01 nM). 
 
 The transcriptional activation of immediate early 
transcription factors such as c-fos is thought to be 
essential for mitogen-induced progression through the 
cell [40].  c-fos is a constituent of the immediate early 
transcription factor activator protein 1 (AP-1) 
heterodimeric complex and has been implicated as an 
positive modulator of G1-to-S-phase progression and cell 
proliferation [40, 41, 42].  The induction of the c-fos 
gene involves both transcriptional and post-
transcriptional machinery [43].  Once stimulated, c-fos 
conjoins with c-jun, a transcription factor of the Jun 
family, and forms the heterodimeric complex, AP-1 [43].  
Moreover, oxidative stress and DNA damage can 
stimulate c-fos expression and thus increase AP-1 
transcription factor activity [44, 45].  The c-fos proto-
oncogene plays a vital role in mitogenesis by inducing 
the expression of genes necessary for the activation of 
Gene 
Protein 
Biological 
Function / 
Response 
NRG1+
PCP  
8µg/mL 
PCP  
8µg/mL
NRG1+
PCP  
16µg/mL
PCP 
16µg/mL
 
c-fos 
AP-1 
component 
Signaling-
immediate 
early gene 
 
DNA-
damage 
- 83,714 54,115 229,374
 
HSP70 
Molecular 
chaperone 
 
Oxidative 
stress 
Protein 
alterations 
- 170,584 - 10,000 
 
GADD153 
Cell cycle- 
regulator 
DNA repair
 
DNA-
damage 
- 26,441 - 40,626 
 
p53 
Cell cycle-
regulator 
Apoptosis 
 
DNA-
damage 
- 9,502 28,389 43,458 
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G1 cyclins [46].  For example, cyclin D1 mRNA is 
increased by the upregulation of c-fos [47] and mitosis- 
and mitogen-stimulated cyclin D1 transcription are 
repressed in cells deficient for c-fos and FosB [46].  It is 
well documented that mitogen-stimulated cyclin D1 
requires the PIK3 activity [48, 49] and upon activation, 
PI3K stimulates c-fos transcription [50].  We have 
previously reported that the potential toxicity of PCP 
transcriptionally activates the c-fos gene protein in 
HepG2 cells and in primary catfish hepatocytes [18, 19, 
23].  In the present study, we observed a dose-dependent 
upregulation of the c-fos protein in PCP-treated mouse 
hepatocytes (Figure 3, Table 1).   This finding is 
consistent with our previous results and demonstrates 
similar PCP mechanistic activity across cell lines.  We 
also observed a NRG1-β down regulation or repression 
of c-fos expression; indicating that NRG1-β has the 
ability to attenuate the activation of c-fos expression in 
PCP-treated AML mouse hepatocytes.  
 
 NRG1-β Effect on PCP-Induced HSP70 Expression  
  
The 70-kDa HSP gene, a member of the heat shock 
protein molecular chaperone family, is involved in 
protein folding, translocation, and refolding of 
intermediates and proteases, while ensuring the efficient 
degradation of damaged and short-lived proteins [51]. 
Under stressful conditions, the accumulation of unfolded 
proteins in the ER leads to the induction of 
transcriptionally activated genes that encode molecular 
chaperones and folding enzymes [52]. Upon a variety of 
stress stimuli, signals are transduced from the ER to the 
cytoplasm and the nucleus to eventually result in 
adaptation for survival or induction of apoptosis [53].  
HSP70 is documented as a general anti-apoptosis protein 
where it protects cells from the consequences of 
proteolysis by caspase-3-like proteases [54].  Moreover, 
the HSP70 gene protein is highly associated with the 
inflammatory response in lung epithelium and 
myocardial damage [55, 56].  We have previously shown 
that PCP can potently activate the HSP70 protein in 
HepG2 cells [18, 23].   In the present study, a dose-
dependent increased expression of HSP70 was induced 
as a result of PCP-toxicity (Figure 4, Table 1).  These 
results may be directly linked to the phenomenon in 
which the HSP70 gene enhances a cell signaling cascade 
that initiate protein repair.  In the presence of NRG1-β, 
we observed a down regulation or inhibition of HSP70 
expression in PCP-treated cells at 48 h of exposure.  Our 
results are supported by a recent study that demonstrated 
the ability of NRG1-β to reverse inflammation and 
oxidative stress-related genes in focal ischemia of the rat 
brain and in a rat neuroblastoma cell line [13].  Here, we 
report that NRG1-β has the ability to attenuate 
proteolytic activity as a consequence of PCP-toxicity. 
 
NRG1-β Effect on PCP-Induced GADD153 Expression 
  
The GADD153 gene protein is a CCAAT/enhancer-
binding protein (C/EBP)-related gene whose expression 
is induced in response to growth arrest and DNA damage 
[57].  The mechanism responsible for the activation of 
GADD153 expression after DNA damage remains 
unclear.  GADD153 is induced by DNA- and cellular 
damage in a dose-dependent manner [58, 59].  The 
magnitude of GADD153 expression is proportional to 
the extent of cellular injury with maximal GADD153 
promoter activity occurring under circumstances of 
severe toxicity to the cell [58].  Several investigations 
have reported that the induction of GADD153 is strongly 
correlated with the onset of apoptosis [60, 61].  
Moreover, it has been demonstrated that elevated 
GADD153 expression depletes cells of essential thiols 
and down-regulates Bcl2 expression by inhibiting bcl2 
transcription; thus sensitizing cells for death [58].  
GADD153 is a potent mediator of the p53 gene protein 
in response to a variety of DNA damaging agents, 
inducing directly or indirectly G1 arrest and/or apoptosis 
[62].  We have previously reported that PCP-toxicity can 
induce a dose-dependent GADD153 expression in 
HepG2 cells [18].  In the present study, we also observed 
a dose-dependent elevated expression of the 153-kDa 
GADD protein in PCP-treated hepatocytes at 48 h of 
exposure (Figure 5, Table 1).  Consistent with our 
previous findings, NRG1-β down-regulated or 
completely repressed the GADD153 expression in PCP-
treated hepatocytes. In this study, the GADD153 
expression is consistent with a previous study that 
demonstrated the ability of NRG1-β to reverse stress-
related gene expression [13].   
 
NRG1-β Effect on PCP-Induced on p53 Expression 
  
The p53 gene is a tumor suppressor protein that 
plays a regulatory role in cell cycle control and 
apoptosis.  p53 is a checkpoint molecule in G1 arrest 
caused by DNA damage and is closely dependent on 
transcriptional activation of the CKI p21 target gene 
[63].  Three major events associated with the p53 tumor 
suppressor gene are growth arrest, DNA repair, and 
apoptosis.  Moreover, the ability of p53 to function as a 
sequence-specific DNA-binding protein appears to be 
essential to the function of p53 as a tumor suppressor 
[64, 65].  It has been reported that increased p53 
expression is directly linked to missense mutations, 
which result in loss of its transcriptional activator 
function [66].  Our laboratory has previously reported 
that PCP has the ability to induce a dose-dependent 
expression of the 53-kDa p53 protein in HepG2 cells [18, 
23].  In the present study, NRG1-β attenuated the 
expression of p53 at lower levels of PCP; however, PCP-
treated hepatocytes demonstrated an increase in p53 
expression (Figure 6, Table1).  In support of these 
results, it has been documented that in response to DNA 
damage, cells facilitate a rapid increase in wild-type p53 
levels and a temporarily G1 arrest; allowing time for 
DNA to be repaired before being copied [67].  When 
optimal repair after DNA damage is irreparable, p53 
initiates the signal to promote apoptosis [68].   
 
NRG1-β Effect on PCP-Induced cyclin D1 
  
Cell cycle transition from G1 to S phase is tightly 
regulated by distinct cyclin-dependent kinases (cdks) 
which are instrumental in cell cycle progression [69].   
Cyclin D/Cdk4 complexes phosphorylate the 
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retinoblastoma gene product early in the G1 phase of the 
cell cycle [69].  The 35-kDa cyclin D1 is overexpressed 
in several types of carcinomas and, therefore, suggested 
to play an important role in tumorigenesis and tumor 
progression including hepatocellular carcinoma [70, 71, 
72].   When cyclin D1  is upregulated due to gene 
amplification, gene rearrangement, protein stabilization 
or other mechanisms, cyclin D1 acts as an oncogene by 
intensifying cell transformation, either alone [73] or in 
combination with activated ras [74], thereby shortening 
the G1 phase of the cell
 cycle. Interestingly, the induction 
of apoptosis is closely associated with an increase in 
cyclin D1-dependent kinase activity [75, 76, 77].  
Notably, alterations in cyclin D1/Cdk4 caused by 
inhibition of ErbB2 support a critically role for cyclin 
D1 in ErbB2-mediated cell cycle progression [78].   
Primary hepatocytes in culture readily proliferate in 
response to mitogens such as EGF [79].  Previous studies 
have shown that cyclin D1 is up-regulated during 
hepatocyte proliferation in culture [27, 80, 81].  We have 
previously demonstrated that PCP is capable of 
provoking a mitogenic response in HepG2 cells, primary 
catfish hepatocytes, and AML 12 mouse hepatocytes 
[19, 20, 23].  Results from the present study showed a 
dose-dependent activation of the 35-kDa cyclin D1 
protein in PCP-treated cell in the presence of NRG1-β 
(Figure 7).  However, in the absence of NRG1-β, PCP-
treated cells demonstrated a down-regulated or repressed 
expression of the cyclin D1 protein; probably due to cell 
death at high levels of PCP- toxicity.  These results are 
consistent with previous data in this study that 
demonstrate the protective effects of NRG1-β against 
PCP-toxicity. 
 
NRG1-β Effects on PCP-induced Caspase-3 Expression  
 
Caspases are the major enforcers of cell death, 
serving as molecular executioners to destroy many 
proteins required for maintenance of cellular 
homeostasis [82]. Caspase-3 is a major modulator of 
apoptotic activity.  Apoptotic inhibitors, such as Bcl-2 
and NF-kappa B, play a crucial role in the mechanism of 
anti-apoptosis of tumors [83, 84].  Caspase-3 is highly 
associated with apoptosis and is only cleaved and 
activated once the process of apoptosis is irreversible 
[85, 86].  Interestingly, it has been documented that PKC 
activity precedes the activation of caspase-3 [87].  A 
recent study demonstrated that the overexpression of 
PKC resulted in an increase of apoptosis, whereas its 
inhibition blocked caspase-3 activity and decreased 
apoptosis [87].  We have previously demonstrated that 
PCP causes cell injury and is cytotoxic to HepG2, 
primary catfish hepatocytes, and AML 12 mouse 
hepatocytes [18, 19, 20, 23].  In this study, we clearly 
demonstrate the ability of PCP to induce apoptosis in 
AML 12 mouse hepatocytes.  This event was 
demonstrated by the upregulation of the 32-kDa caspase-
3 protein in PCP-treated hepatocytes (Figure 8).  
Moreover, the caspase-3 protein was down-regulated or 
repressed in the presence of NRG1-β at higher levels of 
PCP.  These results demonstrate the ability NRG1-β can 
exert an anti-apoptotic effect in PCP–treated hepatocytes.  
The mechanism by which NRG1-β attenuates caspase-3 
expression is not clear.  Future studies from our 
laboratory will investigate whether NRG1-β regulates 
pro-apoptotic gene expression by interfering with 
various transcriptional signaling pathways. 
 
Conclusions 
  
We have demonstrated that NRG1-β plays a 
cytoprotective role in AML 12 mouse hepatocytes 
exposed to PCP.  NRG1-β was able to protect AML 12 
mouse hepatocytes from cell injury by suppressing the 
toxic effects of PCP. NRG1-β has the ability to attenuate 
stress-related gene expression in PCP-treated AML 12 
mouse hepatocytes. Western-blot analysis strongly 
indicated that PCP has the ability to cause oxidative 
stress and inflammatory reaction (c-fos), growth arrest 
and DNA damage (GADD153), proteotoxic effects 
(HSP70), and cell cycle arrest as consequence of DNA 
damage (p53). A mitogenic response was demonstrated 
by the upregulation of the 35-kDa cyclin D1 protein in 
PCP-treated hepatocytes. PCP-induced apoptosis was 
demonstrated by the overexpression of the 32-kDa 
caspase-3 protein. PCP-induced toxicity was attenuated 
or reversed in the presence of NRG1-β. To our 
knowledge, the anti-inflammatory activity of NRG1-β, is 
a novel finding and could represent efficient treatment 
for hepatic inflammatory disorders.  Future studies from 
our laboratory will investigate the regulatory activity of 
NRG1- β on pro-inflammatory gene expression. 
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